Daniela Esposito

University of Gothenburg, Sahlgrenska Academy
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Acromegaly is a rare endocrine disorder caused by excessive growth hormone (GH) production, due, in the vast majority of cases, to the presence of a GH-secreting pituitary tumour. The chronic elevation of GH and the resulting high circulating levels of insulin-like growth factor-1 (IGF-1) cause the characteristic tissue overgrowth and a number of associated comorbidities, including several metabolic changes, such as glucose intolerance and overt diabetes mellitus (DM). Elevated GH concentrations directly attenuate insulin signalling and stimulate lipolysis, decreasing glucose uptake in peripheral tissues, thus leading to the development of impaired glucose tolerance and DM. Acromegaly treatment aims to normalize plasma GH and IGF-1 levels using surgery, medical treatment, or radiotherapy. The effect of the different medical therapies on glucose homeostasis varies. This literature review explores the impact of the currently available pharmacological therapies for acromegaly (first- and second-generation somatostatin receptor ligands, a GH receptor antagonist, and dopamine agonists) on glucose homeostasis. We also discuss the underlying biological mechanisms through which they impact glucose metabolism.

Year:

2025

Background Pasireotide long-acting release (PasiLAR), a somatostatin multireceptor ligand, is effective in achieving biochemical control but can increase the risk of hyperglycemia in acromegaly. However, the impact of PasiLAR on lipid and glucose metabolism in patients with acromegaly has not been systematically studied. This systematic review aimed at synthesizing evidence on PasiLAR effects (as monotherapy or combination therapy with pegvisomant) on lipid and glucose metabolism in patients with acromegaly. Methods MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2000 and 2024. Prospective and retrospective studies reporting metabolic outcomes before and under PasiLAR treatment for a minimum follow-up of 6 months. Two reviewers screened eligible publications (3441), extracted outcomes, and assessed risk of bias. Results Nineteen studies (896 patients) were included in the meta-analysis. PasiLAR was associated with increased fasting plasma glucose (FPG) (mean difference [MD] 23.4 mg/dL, 95% confidence interval [95%CI] 18.8–28.1]) and glycated hemoglobin (HbA 1c ) (MD 0.5%, 95%CI 0.4–0.7). A higher frequency of diabetes mellitus (DM) was observed after treatment (odds ratio 3.7, 95%CI 2.9–4.7). No significant changes in triglycerides, total cholesterol, or low-density lipoprotein cholesterol (LDL-C), and a modest but significant increase in high-density lipoprotein cholesterol (HDL-C) were recorded (MD 6.2 mg/dL, 95%CI 1.4–10.9]). Conclusions In this large meta-analysis, PasiLAR was associated with increased HDL-C, FPG, HbA1c, and frequency of DM in patients with acromegaly. There was no effect on triglycerides, total cholesterol, and LDL-C. PROSPERO registration number CRD42024544686.

Year:

2025

Diet composition and energy intake directly modulate the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) axis, and indirectly through endogenous regulators such as insulin, ghrelin, and adipokines. Moreover, diet has a well-established role in the prevention and management of various metabolic and cardiovascular comorbidities in the general population. Acromegaly, caused by an endogenous overproduction of GH, is an endocrine disorder associated with increased risk of metabolic and cardiovascular comorbidities and excess mortality. The treatment of acromegaly aims to normalize GH and IGF-1 levels, manage complications, and reduce mortality. There is a considerable gap in research regarding the specific influence of diet on biochemical control and complications in acromegaly; therefore, consensus guidelines for managing metabolic and cardiovascular complications in acromegaly generally recommend the same nutritional interventions as those for the general population, even though the underlying pathogenic mechanisms often differ. This narrative review aims to provide an overview of how nutrition modulates the GH/IGF-1 axis and to summarize current evidence on the effect of various macronutrients and dietary patterns on biochemical control and comorbidity management in patients with acromegaly. Evidence in healthy individuals suggests that diets low in animal-derived proteins, combined with moderate fat and carbohydrate intake, may lower GH/IGF-1 activity. Nevertheless, further research is needed in patients with acromegaly to determine whether dietary interventions, such as those found effective in the general population, can help achieve biochemical control and effectively manage metabolic and cardiovascular comorbidities in this specific group.

Year:

2025

Year:

2025

Introduction Adrenal insufficiency (AI) is a rare disorder characterised by an impaired secretion of glucocorticoids from the adrenal glands. Treatment strategies for AI have developed over time with reduced glucocorticoid replacement doses and improved circadian exposure regimens, but whether this has resulted in better survival is unknown. The main purpose of this systematic review is to gather and synthesise available evidence on long-term mortality in patients with AI. The secondary aim is to study causes of death, with focus on cardiovascular and infectious diseases, in AI patients. Methods and analysis Studies published from the inception of respective databases (Medline, Embase, Cochrane and Web of Science) until the end of May 2023 will be systematically synthetised. Observational studies with a reference population will be included, and their quality will be assessed using the Newcastle-Ottawa scale. Data collected will be narratively integrated and a meta-analysis will be performed to pool data from studies considered homogeneous. The systematic review will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This will be the first systematic review assessing mortality and causes of death in AI patients. The findings of this systematic review will be of value for both patients and healthcare providers. Ethics and dissemination This systematic review does not require ethical approval or informed consent because it will be based on previously published data only and does not implicate any direct contact with individual patients. The research results will be presented at scientific conferences and submitted for publication in an internationally recognised peer-reviewed scientific journal. PROSPERO registration number CRD42023416253.

Year:

2024

Collaborators (11)

Wiebke Arlt

Professor of Transdisciplinary Medicine and Head of Department

Imperial College London

UNITED KINGDOM
View details

NIKI KARAVITAKI

University of Birmingham

UNITED KINGDOM
View details

Diego Ferone

Assistant Professor

University of Genova

ITALY
View details

Davide Maggi

University of Genoa

ITALY
View details

Gudmundur Johannsson

University of Gothenburg

SWEDEN
View details

Sabrina Chiloiro

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

ITALY
View details

Federico Gatto

University of Genova

ITALY
View details

Alessandra Puddu

University of Genova

ITALY
View details

Annamaria Colao

Professore Ordinario

Università degli Studi di Napoli Federico II

ITALY
View details

Maria Fleseriu

Oregon Health & Science University

UNITED STATES
View details

Alexandra Kautzky-Willer

Professor of Gender Medicine

Medical University of Vienna

AUSTRIA
View details